Spherix Incorporated (NASDAQ: SPEX), an intellectual property development company committed to the fostering of technology, today announced the addition of Dr. Scott T. Tagawa to the Company's Technology Advisory Board. The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena.
Dr. Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine. After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. After completing his Internship and Residency training there, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. In August 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medicine in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theragnostic in prostate cancer. He was promoted to Associate Professor of Clinical Medicine and of Clinical Urology in 2013. Dr. Tagawa is the Weill Cornell Medicine principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple "top doctor" award lists.
Anthony Hayes, the Chief Executive Officer of Spherix stated, "Dr. Tagawa is clearly a leader in his field, with an exceptionally distinguished career. We are honored to have him on our advisory board and grateful for his assistance in vetting opportunities for the Company."
About Spherix Incorporated
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by participation in the development of new technology. Spherix draws on portfolios of pioneering technology to support product innovation.
